Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer (Q33811362)

29 July 2017

title

Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer (English)

1 reference

29 July 2017

1 reference

Jan B Howes

1

1 reference

29 July 2017

Paul L de Souza

2

1 reference

29 July 2017

Leanne West

3

1 reference

29 July 2017

Li Jiu Huang

4

1 reference

29 July 2017

Laurence G Howes

5

1 reference

29 July 2017

publication date

3 February 2011

1 reference

BMC Clinical Pharmacology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

page(s)

1

1 reference

Phenoxodiol inhibits growth of metastatic prostate cancer cells

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Modulation of apoptosis to reverse chemoresistance

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

ECTO-NOX target for the anticancer isoflavene phenoxodiol.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Phenoxodiol, a novel approach for the treatment of ovarian cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors

4 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-1

The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-1

Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague–Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-1

Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-1

Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-1

Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045896

Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21291562

12 December 2020

inferred from PubMed ID database lookup

NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21291562

12 December 2020

inferred from PubMed ID database lookup

Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21291562

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/1472-6904-11-1

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ugezdub7lfenhm2v3hdycbr2ku

30 July 2022

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/1472-6904-11-1

release_ugezdub7lfenhm2v3hdycbr2ku

9 September 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ugezdub7lfenhm2v3hdycbr2ku

30 July 2022

https://api.fatcat.wiki/v0/release/ugezdub7lfenhm2v3hdycbr2ku

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/ugezdub7lfenhm2v3hdycbr2ku

1 reference

30 July 2022